Compare ARK Genomic Revolution ETF (ARKG) vs Meta Platforms Inc (META) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Meta Platforms Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Meta Platforms Inc trades at $664.84 (market cap $1.70T). The key difference: Meta Platforms Inc pays a 0.31% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Meta Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | META | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $790.00 |
52-Week Low | $23.09 | $525.72 |
Market Cap | — | $1.70T |
Volume | — | 24,093,972 |
Enterprise Value | — | $1.70T |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Meta Platforms (META) trades at $669.21, up 5.97% in the last 24 hours, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $201B and net income of $60.5B, maintaining high profitability margins. Recent catalysts include the launch of Muse Spark AI model and consistent earnings beats, with Q1 2026 EPS of $7.31 exceeding expectations of $6.70.
Outlook remains positive with analyst consensus price target of $820.94 representing 22.7% upside potential. Key risks include ongoing regulatory litigation and high capital expenditures for AI infrastructure. The stock trades at reasonable valuations with P/E of 24.33 and P/S of 7.99, supported by strong institutional ownership and 79% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
